{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T19:48:20Z","timestamp":1781552900021,"version":"3.54.5"},"reference-count":49,"publisher":"Public Library of Science (PLoS)","issue":"5","license":[{"start":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T00:00:00Z","timestamp":1746576000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"atai Fellowship"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p>Opioid use disorder (OUD) is a debilitating health condition that is associated with significant morbidity and mortality in the U.S. While preliminary studies have demonstrated that psilocybin is associated with lowered odds of OUD, current research in this domain suffers from a lack of investigation into the impact of race\/ethnicity on this association.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Objective:<\/jats:title>\n<jats:p>To assess the impact of race and ethnicity on the association between psilocybin use and lowered odds of OUD using data from the National Survey on Drug Use and Health (2002\u20132019) (N = 706,891).<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Method:<\/jats:title>\n<jats:p>I used survey-weighted multivariable logistic regression to test whether race\/ethnicity moderates the association between psilocybin use and lowered odds of OUD. Subsequently, I stratified my sample by race and ethnicity and assessed the associations between psilocybin and OUD for individual racial and ethnic groups (White, Black, Indigenous, Asian, Multiracial, Hispanic). My analysis plan was pre-registered.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>Race and ethnicity significantly moderated the association between psilocybin and OUD. Furthermore, when I stratified my sample by race and ethnicity, only White participants and Hispanic participants demonstrated a link between psilocybin and lowered odds of OUD (White aOR: 0.84; Hispanic aOR: 0.68). For Black, Asian, Indigenous, and Multiracial participants, psilocybin did not share a significant association with OUD.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>Race and ethnicity moderate the associations between psilocybin and OUD. Future longitudinal, experimental, and qualitative research is needed to better understand the pattern of associations I observed in this study.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0321461","type":"journal-article","created":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T20:17:46Z","timestamp":1746649066000},"page":"e0321461","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":2,"title":["Race\/ethnicity moderates the associations between lifetime psilocybin use and opioid use disorder"],"prefix":"10.1371","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2426-310X","authenticated-orcid":true,"given":"Grant","family":"Jones","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2025,5,7]]},"reference":[{"issue":"4","key":"pone.0321461.ref001","doi-asserted-by":"crossref","DOI":"10.1097\/ADM.0000000000000606","article-title":"Mortality Among People With Opioid Use Disorder: A Systematic Review and Meta-analysis","volume":"14","author":"A Bahji","year":"2020","journal-title":"J Addict Med"},{"key":"pone.0321461.ref002","doi-asserted-by":"crossref","first-page":"108350","DOI":"10.1016\/j.drugalcdep.2020.108350","article-title":"The economic burden of opioid use disorder and fatal opioid overdose in the United States, 2017","volume":"218","author":"C Florence","year":"2021","journal-title":"Drug Alcohol Depend"},{"key":"pone.0321461.ref003","doi-asserted-by":"crossref","DOI":"10.7326\/AITC202201180","article-title":"Opioid use disorder","volume":"175","author":"J Taylor","year":"2022","journal-title":"Annals of Internal Medicine"},{"issue":"1","key":"pone.0321461.ref004","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41572-019-0137-5","article-title":"Opioid use disorder","volume":"6","author":"J Strang","year":"2020","journal-title":"Nat Rev Dis Primers"},{"issue":"6","key":"pone.0321461.ref005","doi-asserted-by":"crossref","first-page":"202","DOI":"10.15585\/mmwr.mm7006a4","article-title":"Trends and Geographic Patterns in Drug and Synthetic Opioid Overdose Deaths - United States, 2013-2019","volume":"70","author":"CL Mattson","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"2","key":"pone.0321461.ref006","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2018.0217","article-title":"The Burden of Opioid-Related Mortality in the United States","volume":"1","author":"T Gomes","year":"2018","journal-title":"JAMA Netw Open"},{"key":"pone.0321461.ref007","doi-asserted-by":"crossref","first-page":"2574","DOI":"10.1038\/s41598-022-06580-2","article-title":"Exploring protective associations between the use of classic psychedelics and cocaine use disorder: a population-based survey study","volume":"12","author":"G Jones","year":"2022","journal-title":"Scientific Reports"},{"key":"pone.0321461.ref008","doi-asserted-by":"crossref","first-page":"10578","DOI":"10.1038\/s41598-022-14809-3","article-title":"Associations between classic psychedelics and nicotine dependence in a nationally representative sample","volume":"12","author":"G Jones","year":"2022","journal-title":"Scientific Reports"},{"issue":"11","key":"pone.0321461.ref009","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1177\/0269881114548296","article-title":"Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction","volume":"28","author":"MW Johnson","year":"2014","journal-title":"J Psychopharmacol"},{"key":"pone.0321461.ref010","doi-asserted-by":"crossref","first-page":"103518","DOI":"10.1016\/j.drugpo.2021.103518","article-title":"Psychedelic use is associated with reduced daily opioid use among people who use illicit drugs in a Canadian setting","volume":"100","author":"E Argento","year":"2022","journal-title":"International Journal of Drug Policy"},{"issue":"7","key":"pone.0321461.ref011","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1177\/0269881116684335","article-title":"An online survey of tobacco smoking cessation associated with naturalistic psychedelic use","volume":"31","author":"MW Johnson","year":"2017","journal-title":"J Psychopharmacol"},{"issue":"5","key":"pone.0321461.ref012","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1177\/0269881117691453","article-title":"The association of psychedelic use and opioid use disorders among illicit users in the United States","volume":"31","author":"VD Pisano","year":"2017","journal-title":"J Psychopharmacol"},{"issue":"4","key":"pone.0321461.ref013","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1055\/a-1341-1907","article-title":"Classical Psychedelics as Therapeutics in Psychiatry - Current Clinical Evidence and Potential Therapeutic Mechanisms in Substance Use and Mood Disorders","volume":"54","author":"LJ Mertens","year":"2021","journal-title":"Pharmacopsychiatry"},{"issue":"2","key":"pone.0321461.ref014","doi-asserted-by":"crossref","first-page":"101","DOI":"10.2174\/1874473708666150107120011","article-title":"Psychedelics as medicines for substance abuse rehabilitation: evaluating treatments with LSD, Peyote, Ibogaine and Ayahuasca","volume":"7","author":"M Winkelman","year":"2014","journal-title":"Curr Drug Abuse Rev"},{"issue":"3","key":"pone.0321461.ref015","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1177\/0269881114565144","article-title":"Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study","volume":"29","author":"MP Bogenschutz","year":"2015","journal-title":"J Psychopharmacol"},{"key":"pone.0321461.ref016","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1002\/dta.1376","article-title":"Therapeutic mechanisms of classic hallucinogens in the treatment of addictions: from indirect evidence to testable hypotheses","volume":"4","author":"MP Bogenschutz","year":"2012","journal-title":"Drug Test Anal"},{"key":"pone.0321461.ref017","doi-asserted-by":"crossref","first-page":"136","DOI":"10.3389\/fpsyt.2018.00136","article-title":"Assessment of alcohol and tobacco use disorders among religious users of ayahuasca","volume":"9","author":"P Barbosa","year":"2018","journal-title":"Front Psychiatry"},{"issue":"10","key":"pone.0321461.ref018","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1001\/jamapsychiatry.2022.2096","article-title":"Percentage of Heavy Drinking Days Following Psilocybin-Assisted Psychotherapy vs Placebo in the Treatment of Adult Patients With Alcohol Use Disorder: A Randomized Clinical Trial","volume":"79","author":"MP Bogenschutz","year":"2022","journal-title":"JAMA Psychiatry"},{"key":"pone.0321461.ref019","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.pharmthera.2003.11.002","article-title":"Hallucinogens","volume":"101","author":"DE Nichols","year":"2004","journal-title":"Pharmacol Ther"},{"issue":"1","key":"pone.0321461.ref020","doi-asserted-by":"crossref","first-page":"4099","DOI":"10.1038\/s41598-022-08085-4","article-title":"Associations between classic psychedelics and opioid use disorder in a nationally-representative U.S. adult sample","volume":"12","author":"G Jones","year":"2022","journal-title":"Sci Rep"},{"issue":"9","key":"pone.0321461.ref021","article-title":"Racial and Ethnic Disparities in Drug Overdose Deaths in the US During the COVID-19 Pandemic","volume":"5","author":"B Han","year":"2022","journal-title":"JAMA Netw Open"},{"key":"pone.0321461.ref022","doi-asserted-by":"crossref","first-page":"106845","DOI":"10.1016\/j.ypmed.2021.106845","article-title":"Growing racial\/ethnic disparities in overdose mortality before and during the COVID-19 pandemic in California","volume":"153","author":"J Friedman","year":"2021","journal-title":"Prev Med"},{"issue":"1","key":"pone.0321461.ref023","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1186\/s12888-018-1824-6","article-title":"Inclusion of people of color in psychedelic-assisted psychotherapy: a review of the literature","volume":"18","author":"TI Michaels","year":"2018","journal-title":"BMC Psychiatry"},{"key":"pone.0321461.ref024","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1080\/09687637.2021.1897331","article-title":"Whitewashing psychedelics: racial equity in the emerging field of psychedelic-assisted mental health research and treatment","volume":"28","author":"J Thrul","year":"2021","journal-title":"Drugs Educ Prevent Policy"},{"issue":"1","key":"pone.0321461.ref025","doi-asserted-by":"crossref","first-page":"16976","DOI":"10.1038\/s41598-022-18645-3","article-title":"Race and ethnicity moderate the associations between lifetime psychedelic use (MDMA and psilocybin) and psychological distress and suicidality","volume":"12","author":"GM Jones","year":"2022","journal-title":"Sci Rep"},{"issue":"1","key":"pone.0321461.ref026","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1177\/02698811221127304","article-title":"Race and ethnicity moderate the associations between lifetime psychedelic use (MDMA\/ecstasy and psilocybin) and major depressive episodes","volume":"37","author":"GM Jones","year":"2023","journal-title":"J Psychopharmacol"},{"key":"pone.0321461.ref027","doi-asserted-by":"crossref","first-page":"1169692","DOI":"10.3389\/fpsyt.2023.1169692","article-title":"Race and ethnicity moderate the associations between lifetime psilocybin use and crime arrests","volume":"14","author":"G Jones","year":"2023","journal-title":"Front Psychiatry"},{"key":"pone.0321461.ref028","article-title":"Association between lifetime hallucinogen use and psychological distress varies by sexual identity in a nationally representative sample","author":"B Altman","year":"2024","journal-title":"Journal of Psychopharmacology"},{"key":"pone.0321461.ref029","doi-asserted-by":"crossref","first-page":"1169686","DOI":"10.3389\/fpsyt.2024.1169686","article-title":"Race and ethnicity moderate the associations between lifetime psilocybin use and past year hypertension","volume":"15","author":"GM Jones","year":"2024","journal-title":"Front Psychiatry"},{"key":"pone.0321461.ref030","article-title":"Minorities\u2019 Diminished Psychedelic Returns: Income and Educations Impact on Whites, Blacks, Hispanics, and Asians","author":"SM Vina","year":"2024","journal-title":"J Racial Ethn Health Disparities"},{"key":"pone.0321461.ref031","article-title":"Minorities\u2019 diminished psychedelic returns","volume":"9","author":"SM Vi\u00f1a","year":"2023","journal-title":"Drug Science, Policy and Law"},{"key":"pone.0321461.ref032","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.jad.2024.10.058","article-title":"Examining differences in the effects and contexts of naturalistic psilocybin use for White participants vs. Participants of Color: A longitudinal online survey study","volume":"370","author":"G Jones","year":"2025","journal-title":"J Affect Disord"},{"key":"pone.0321461.ref033","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-3-642-55214-4_96-1","article-title":"The History of psychedelics in medicine","volume-title":"Handb. Psychoaktive Subst","author":"B. Sessa","year":"2016"},{"key":"pone.0321461.ref034","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1556\/2054.2020.00159","article-title":"Use of psilocybin (\u201cmushrooms\u201d) among US adults: 2015\u20132018","volume":"5","author":"A Yockey","year":"2021","journal-title":"J Psychedelic Stud"},{"issue":"7","key":"pone.0321461.ref035","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1177\/0269881118754710","article-title":"Psychedelics and the essential importance of context","volume":"32","author":"RL Carhart-Harris","year":"2018","journal-title":"J Psychopharmacol"},{"issue":"9","key":"pone.0321461.ref036","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0138511","article-title":"Racism as a Determinant of Health: A Systematic Review and Meta-Analysis","volume":"10","author":"Y Paradies","year":"2015","journal-title":"PLoS One"},{"key":"pone.0321461.ref037","doi-asserted-by":"crossref","first-page":"699049","DOI":"10.3389\/fpubh.2021.699049","article-title":"Poverty, Racism, and the Public Health Crisis in America","volume":"9","author":"BM Beech","year":"2021","journal-title":"Front Public Health"},{"key":"pone.0321461.ref038","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1111\/1475-6773.13222","article-title":"Understanding how discrimination can affect health","volume":"54","author":"DR Williams","year":"2019","journal-title":"Health Serv Res"},{"issue":"5","key":"pone.0321461.ref039","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1111\/jep.12894","article-title":"Racism & Health: A public health perspective on racial discrimination","volume":"24","author":"SS Cobbinah","year":"2018","journal-title":"J Eval Clin Pract"},{"key":"pone.0321461.ref040","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.socscimed.2013.09.006","article-title":"Systemic racism and U.S. health care","volume":"103","author":"J Feagin","year":"2014","journal-title":"Soc Sci Med"},{"issue":"1","key":"pone.0321461.ref041","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1177\/0022042616678614","article-title":"Comparing Black and White Drug Offenders: Implications for Racial Disparities in Criminal Justice and Reentry Policy and Programming","volume":"47","author":"A Rosenberg","year":"2017","journal-title":"J Drug Issues"},{"issue":"4","key":"pone.0321461.ref042","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1080\/09540261.2018.1474185","article-title":"Awe: a putative mechanism underlying the effects of classic psychedelic-assisted psychotherapy","volume":"30","author":"P Hendricks","year":"2018","journal-title":"International Review of Psychiatry"},{"key":"pone.0321461.ref043","doi-asserted-by":"crossref","first-page":"917199","DOI":"10.3389\/fpsyt.2022.917199","article-title":"Psychedelics, Mystical Experience, and Therapeutic Efficacy: A Systematic Review","volume":"13","author":"K Ko","year":"2022","journal-title":"Front Psychiatry"},{"issue":"9","key":"pone.0321461.ref044","article-title":"Psychedelics and health behaviour change","volume":"35","author":"P Teixeira","year":"2021","journal-title":"Journal of Psychopharmacology"},{"issue":"9","key":"pone.0321461.ref045","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1177\/0269881119845793","article-title":"Cessation and reduction in alcohol consumption and misuse after psychedelic use","volume":"33","author":"A Garcia-Romeu","year":"2019","journal-title":"J Psychopharmacol"},{"issue":"7","key":"pone.0321461.ref046","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1177\/0269881118780612","article-title":"Psychedelic therapy for smoking cessation: Qualitative analysis of participant accounts","volume":"32","author":"T Noorani","year":"2018","journal-title":"J Psychopharmacol"},{"key":"pone.0321461.ref047","doi-asserted-by":"crossref","first-page":"955","DOI":"10.3389\/fpsyt.2019.00955","article-title":"Persisting Reductions in Cannabis, Opioid, and Stimulant Misuse After Naturalistic Psychedelic Use: An Online Survey","volume":"10","author":"A Garcia-Romeu","year":"2020","journal-title":"Front Psychiatry"},{"key":"pone.0321461.ref048","doi-asserted-by":"crossref","first-page":"108589","DOI":"10.1016\/j.jsat.2021.108589","article-title":"The intersection of race and opioid use disorder treatment: A quantitative analysis","volume":"131","author":"RM Entress","year":"2021","journal-title":"J Subst Abuse Treat"},{"key":"pone.0321461.ref049","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.drugalcdep.2016.10.015","article-title":"Treatment utilization among persons with opioid use disorder in the United States","volume":"169","author":"L-T Wu","year":"2016","journal-title":"Drug Alcohol Depend"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0321461","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T20:17:54Z","timestamp":1746649074000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0321461"}},"subtitle":[],"editor":[{"given":"Edward","family":"Chiyaka,","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,5,7]]},"references-count":49,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,5,7]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0321461","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,7]]}}}